Early molecular response in chronic myeloid leukemia patients predicts future response status
| Autor: | Srihari Uppalapati, Sangeeta Jiwtani, Raghunadharao Digumarti, Sailaja Kagita, Vijay Gandhi Linga, S. Gundeti |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Adolescent Fusion Proteins bcr-abl Drug resistance Piperazines Myelogenous European LeukemiaNet Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine medicine Humans Child neoplasms business.industry Myeloid leukemia Imatinib General Medicine Middle Aged medicine.disease Leukemia Pyrimidines Imatinib mesylate Molecular Response Benzamides Immunology Imatinib Mesylate Female business medicine.drug |
| Zdroj: | Tumor Biology. 35:4443-4446 |
| ISSN: | 1423-0380 1010-4283 |
| DOI: | 10.1007/s13277-013-1585-2 |
| Popis: | Imatinib is the frontline therapy for chronic myeloid leukemia (CML) management. Most of the CML patients achieve major responses, but a proportion (nearly 25-35%) of them develop drug resistance. Molecular monitoring using quantitative real-time PCR at regular intervals according to European LeukemiaNet (ELN) helps in the assessment of long-term outcomes in imatinib-treated CML patients. Eighty-four CML patient samples (42 at diagnosis and 42 at 3-month intervals from the same patients) were analyzed for Bcr-Abl transcript levels. Quantification results revealed that the patients with10% Bcr-Abl levels at 3 months had higher rates of complete cytogenetic response (CCyR) and optimal responses compared to patients with10% Bcr-Abl levels (P 0.0001). Patients with10% Bcr-Abl levels were found to have 25.0% of suboptimal response and 3.57% of failure to imatinib at standard dose. Hence, the present study confirms that early molecular monitoring at 3 months after imatinib initiation helps in predicting the concurrent cytogenetic response and treatment optimization in CML patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink